triciribine has been researched along with Disease Exacerbation in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adler, AS; Chang, HY; Chou, J; Collins, CC; Dijkgraaf, GJ; Gray, JW; Griffith, OL; Huang, G; Korkola, JE; Kouros-Mehr, H; Krig, SR; Lawson, DA; Littlepage, LE; Qu, K; Rugo, HS; Sternlicht, MD; Sweeney, CA; Werb, Z; Xue, Q; Yaswen, P | 1 |
1 other study(ies) available for triciribine and Disease Exacerbation
| Article | Year |
|---|---|
The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression.
Topics: Animals; Antibiotics, Antineoplastic; Biomarkers, Tumor; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; Neoplastic Stem Cells; NIH 3T3 Cells; Oligonucleotide Array Sequence Analysis; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleosides; Survival Analysis; Trans-Activators; Xenograft Model Antitumor Assays | 2012 |